Table 1.
Patient demographics and baseline clinical characteristics (safety population)
|
Demographics |
No |
Eltrombopag |
Eltrombopag |
Eltrombopag |
Total |
|---|---|---|---|---|---|
| |
Eltrombopag |
75 mg |
100 mg |
150 mg |
(N = 15) |
| (n = 3)a | (n = 7) | (n = 4) | (n = 1) | ||
| Median age, y (range) |
56.0 (20–65) |
48.0 (38–62) |
30.5 (23–44) |
59.0 |
44.0 (20–65) |
| Gender, n (%) |
|
|
|
|
|
| Female |
1 (33) |
4 (57) |
2 (50) |
1 (100) |
8 (53) |
| Male |
2 (67) |
3 (43) |
2 (50) |
0 (0) |
7 (47) |
| Race, n (%) |
|
|
|
|
|
| Hispanic or Latino |
1 (33) |
0 (0) |
2 (50) |
0 (0) |
3 (20) |
| Not Hispanic or Latino |
2 (67) |
7 (100) |
2 (50) |
1 (100) |
12 (80) |
|
Baseline clinical characteristics |
|
|
|
||
| Median baseline platelet count, 1000/μL (range) |
256.0 |
300.0 |
264.0 |
388.0 |
281.0 |
| (218–371) |
(197–368) |
(180–595) |
|
(180–595) |
|
| ECOG PS |
|
|
|
|
|
| ECOG 0, n (%) |
0 (0) |
6 (86) |
0 (0) |
1 (100) |
7 (47) |
| ECOG 1, n (%) | 3 (100) | 1 (14) | 4 (100) | 0 (0) | 8 (53) |
aPatients were withdrawn prior to receiving eltrombopag during the second cycle.
ECOG PS, Eastern Cooperative Oncology Group Performance Status.